Teachers Retirement System of The State of Kentucky boosted its position in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 24.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,522 shares of the biopharmaceutical company’s stock after purchasing an additional 10,304 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Ultragenyx Pharmaceutical were worth $2,436,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of RARE. SG Americas Securities LLC acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $156,000. B. Riley Financial Inc. acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth about $213,000. Aperio Group LLC acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth about $254,000. Verity Asset Management Inc. acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth about $306,000. Finally, Canada Pension Plan Investment Board acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $330,000. 87.19% of the stock is owned by institutional investors and hedge funds.
Shares of Ultragenyx Pharmaceutical stock opened at $51.26 on Monday. Ultragenyx Pharmaceutical Inc has a one year low of $41.67 and a one year high of $86.14.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The firm had revenue of $2.41 million during the quarter, compared to the consensus estimate of $0.75 million. During the same period last year, the firm posted ($1.75) earnings per share. equities research analysts expect that Ultragenyx Pharmaceutical Inc will post -6.25 EPS for the current fiscal year.
A number of equities analysts have issued reports on the company. BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Robert W. Baird reaffirmed a “buy” rating and issued a $70.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 23rd. Bank of America upped their target price on Ultragenyx Pharmaceutical from $60.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. Morgan Stanley reaffirmed an “equal weight” rating and issued a $60.00 target price (up previously from $57.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $66.00 target price (down previously from $68.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the stock. Ultragenyx Pharmaceutical has an average rating of “Buy” and a consensus target price of $68.94.
WARNING: “Teachers Retirement System of The State of Kentucky Purchases 10,304 Shares of Ultragenyx Pharmaceutical Inc (RARE)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/03/19/teachers-retirement-system-of-the-state-of-kentucky-purchases-10304-shares-of-ultragenyx-pharmaceutical-inc-rare.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.